Intercept Pharmaceuticals | Bénéfice Avant Impôts



Bénéfice Avant Impôts Changement Date
Acadia Pharmaceuticals USD 44.6M 4.38M 2025-09
Alnylam Pharmaceuticals USD 161.14M 77.83M 2025-12
Amarin USD -8.12M 5.34M 2025-09
Amgen USD 3.92B 2.35B 2025-09
Arrowhead Research USD 28.27M 7.85M 2025-12
AstraZeneca USD 3.24B 117M 2025-09
Biogen USD 557.3M 186.7M 2025-09
Bristol-Myers Squibb USD 3.11B 1.34B 2025-09
Eli Lilly USD 7.23B 456M 2025-09
Enanta Pharmaceuticals USD -22.71M 95.08M 2024-12
Esperion Therapeutics USD 67.66M 3.6M 2024-09
Galectin Therapeutics USD -12.37M 880K 2024-06
Gilead Sciences USD 3.64B 1.21B 2025-09
GlaxoSmithKline GBP 1.23B 1.23B 2025-12
Incyte USD 389.94M 92.37M 2025-12
Ionis Pharmaceuticals USD -129M 253M 2025-09
Moderna USD -187M 631M 2025-09
Neurocrine Biosciences USD 239.4M 52.4M 2025-12
Novartis USD 4.2B 335M 2025-09
PTC Therapeutics USD -23.07M 47.98M 2025-09
Regeneron Pharmaceuticals USD 1.76B 244.6M 2025-09
Sangamo BioSciences USD -36.05M 12.94M 2024-06
Sarepta Therapeutics USD -194.05M 347.69M 2025-09
Vertex Pharmaceuticals USD 1.3B 15.8M 2025-09


Intercept Pharmaceuticals Bénéfice Avant Impôts - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - Feb 2026.